Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Oral pathogenic bacteria associated with gingivitis primarily consist of supragingival plaque biofilms dominated by gram-positive cocci and rods, such as Streptococcus mitis/oralis, Streptococcus gordonii/sanguinis, Veillonella dispar/parvula, and various Neisseria, Haemophilus, and Capnocytophaga species, which prevail in healthy states but shift in abundance to initiate plaque-induced inflammation. These microbes adhere to tooth surfaces, form biofilms, and trigger localized gingival swelling, redness, and bleeding upon probing without involving deeper periodontal structures like cementum or bone. Dysbiosis involving increased Fusobacterium nucleatum, Porphyromonas species, and early pathogens marks the transition from health to gingivitis, preceding periodontitis if untreated. Unlike specific periodontitis pathogens like the "red complex" (Porphyromonas gingivalis, Tannerella forsythia, Treponema denticola), gingivitis-associated bacteria are not singular targets but collective communities targeted mechanically via brushing or chemically with antiseptics. Therapeutic strategies focus on plaque disruption rather than species-specific antimicrobials, emphasizing prevention through oral hygiene to reverse reversible inflammation.
Disruption of bacterial cell membranes; Inhibition of bacterial adhesion and biofilm formation; Reduction of plaque accumulation
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Oral pathogenic bacteria associated with gingivitis.